Healthcare
Pharming Group N.V.(PHAR)
Live Price
Offline$12.87
+1.77% today
1Y Change
+24.18%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $1.19B
- Revenue Growth
- +26.9%
- EPS Growth
- +123.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharming Group N.V. (PHAR) is a Healthcare stock with a market cap of $1.19B and listed on NASDAQ. The stock last traded around $12.87 and up 24.2% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +26.9%, EPS growth of +123.5%, a dividend yield of 0.0%. What stands out right now is revenue +26.9%, EPS +123.5%, free cash flow +2003.3% with operating margin 5.7% and ROIC 1.1%. Valuation already assumes a fairly strong business story at P/E 385.8 and price/sales 3.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PHAR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+26.9% vs +7.6% peer median
Operating Margin
Below sector median
+5.7% vs +19.4% peer median
P/E
Above sector median
385.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +26.9% and EPS at +123.5%, with operating margin around 5.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +10.0% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +8.2% | +8.0% | +4.5% |
2026 Mar 12, 2026 | -53.3% | -4.2% | +2.2% | +12.9% |
2025 Nov 6, 2025 | +100.0% | +5.0% | +19.9% | +13.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHAR
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PHAR Max Drawdown
-43.34%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHAR and SPY.
Company Overview
Pharming Group N.V.
NASDAQ Global Market
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
- Leadership
- Fabrice Chouraqui
- IPO Date
- Dec 23, 2020
- Employees
- 404
- Street Address
- Darwinweg 24
- Mailing
- Leiden, 2333 CR
- Region
- Leiden, NL
- Reporting Currency
- USD
- Investor Line
- 31 71 524 7400
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 385.8
- EV/EBITDA
- 36.4
- Price/Sales
- 3.1
- Price/Book
- 4.0
Growth
- Revenue
- +26.9%
- EPS
- +123.5%
- Free Cash Flow
- +2003.3%
Profitability
- Gross Margin
- 87.9%
- Operating Margin
- 5.7%
- Net Margin
- 0.8%
- ROE
- 1.2%
- ROIC
- 1.1%
Balance Sheet
- Debt/Equity
- 0.42
- Current Ratio
- 2.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.